Medicofarma Biotech Sa Stock Cash Flow From Operations
| MDB Stock | 0.38 0.02 5.00% |
Medicofarma Biotech SA fundamentals help investors to digest information that contributes to Medicofarma Biotech's financial success or failures. It also enables traders to predict the movement of Medicofarma Stock. The fundamental analysis module provides a way to measure Medicofarma Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Medicofarma Biotech stock.
Medicofarma |
Medicofarma Biotech SA Company Cash Flow From Operations Analysis
Medicofarma Biotech's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Medicofarma Biotech SA has 0.0 in Cash Flow From Operations. This is 100.0% lower than that of the Healthcare sector and about the same as Biotechnology & Medical Research (which currently averages 0.0) industry. The cash flow from operations for all Poland stocks is 100.0% higher than that of the company.
Medicofarma Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medicofarma Biotech's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Medicofarma Biotech could also be used in its relative valuation, which is a method of valuing Medicofarma Biotech by comparing valuation metrics of similar companies.Medicofarma Biotech is currently under evaluation in cash flow from operations category among its peers.
About Medicofarma Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medicofarma Biotech SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medicofarma Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medicofarma Biotech SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Medicofarma Biotech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medicofarma Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medicofarma Biotech will appreciate offsetting losses from the drop in the long position's value.Moving together with Medicofarma Stock
Moving against Medicofarma Stock
| 0.88 | DNP | Dino Polska SA | PairCorr |
| 0.54 | ACG | AC SA | PairCorr |
| 0.51 | CDR | CD PROJEKT SA | PairCorr |
| 0.36 | TPE | Tauron Polska Energia | PairCorr |
The ability to find closely correlated positions to Medicofarma Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medicofarma Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medicofarma Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medicofarma Biotech SA to buy it.
The correlation of Medicofarma Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medicofarma Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medicofarma Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medicofarma Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Medicofarma Stock Analysis
When running Medicofarma Biotech's price analysis, check to measure Medicofarma Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medicofarma Biotech is operating at the current time. Most of Medicofarma Biotech's value examination focuses on studying past and present price action to predict the probability of Medicofarma Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medicofarma Biotech's price. Additionally, you may evaluate how the addition of Medicofarma Biotech to your portfolios can decrease your overall portfolio volatility.